MX2020006482A - Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2). - Google Patents

Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2).

Info

Publication number
MX2020006482A
MX2020006482A MX2020006482A MX2020006482A MX2020006482A MX 2020006482 A MX2020006482 A MX 2020006482A MX 2020006482 A MX2020006482 A MX 2020006482A MX 2020006482 A MX2020006482 A MX 2020006482A MX 2020006482 A MX2020006482 A MX 2020006482A
Authority
MX
Mexico
Prior art keywords
epha2
peptide ligands
drug conjugates
ligands specific
bicyclic peptide
Prior art date
Application number
MX2020006482A
Other languages
English (en)
Inventor
Philip Huxley
Liuhong Chen
Silvia Pavan
Rietschoten Katerine Van
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1721259.8A external-priority patent/GB201721259D0/en
Priority claimed from GBGB1804102.0A external-priority patent/GB201804102D0/en
Priority claimed from GBGB1818603.1A external-priority patent/GB201818603D0/en
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of MX2020006482A publication Critical patent/MX2020006482A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a polipéptidos que están unidos covalentemente a andamios moleculares no aromáticos de modo que dos o más bucles de péptidos se sostienen entre los puntos de unión al andamio; en particular, la invención describe péptidos que son aglutinantes de alta afinidad del receptor Eph de tirosina quinasa A2 (EphA2); la invención también incluye conjugados de fármacos que comprenden dichos péptidos, conjugados a uno o más grupos efectores y/o funcionales, a composiciones farmacéuticas que comprenden dichos ligandos de péptidos y conjugados de fármacos y al uso de dichos ligandos de péptidos y conjugados de fármacos para prevenir, suprimir o tratar un enfermedad o trastorno caracterizado por sobreexpresión de EphA2 en tejido enfermo (como un tumor).
MX2020006482A 2017-12-19 2018-12-19 Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2). MX2020006482A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1721259.8A GB201721259D0 (en) 2017-12-19 2017-12-19 Bicyclic peptide ligands specific for EphA2
GBGB1804102.0A GB201804102D0 (en) 2018-03-14 2018-03-14 Bicycle peptide ligands specific for EphA2
GBGB1818603.1A GB201818603D0 (en) 2018-11-14 2018-11-14 Bicyclic peptide ligands specific for epha2
PCT/GB2018/053675 WO2019122860A1 (en) 2017-12-19 2018-12-19 Bicyclic peptide ligands specific for epha2

Publications (1)

Publication Number Publication Date
MX2020006482A true MX2020006482A (es) 2020-12-10

Family

ID=64902125

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020006482A MX2020006482A (es) 2017-12-19 2018-12-19 Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2).
MX2020006474A MX2020006474A (es) 2017-12-19 2018-12-19 Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020006474A MX2020006474A (es) 2017-12-19 2018-12-19 Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2).

Country Status (23)

Country Link
US (5) US11484602B2 (es)
EP (3) EP4053145B1 (es)
JP (3) JP7293231B2 (es)
KR (2) KR20200105839A (es)
CN (2) CN111741771A (es)
AU (3) AU2018387417B2 (es)
BR (2) BR112020012246A2 (es)
CA (2) CA3086257A1 (es)
DK (1) DK3727460T3 (es)
ES (1) ES2922632T3 (es)
HR (1) HRP20220871T1 (es)
HU (1) HUE059126T2 (es)
IL (2) IL275440B2 (es)
LT (1) LT3727460T (es)
MX (2) MX2020006482A (es)
PH (1) PH12020550929A1 (es)
PL (1) PL3727460T3 (es)
PT (1) PT3727460T (es)
SA (1) SA520412268B1 (es)
SG (2) SG11202005494QA (es)
SI (1) SI3727460T1 (es)
TW (1) TWI825046B (es)
WO (2) WO2019122863A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) * 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
BR112020020349A2 (pt) 2018-04-04 2021-01-05 Bicycletx Limited Complexos de peptídeos bicíclicos em heterotandem
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
SG11202110828UA (en) * 2019-04-02 2021-10-28 Bicycletx Ltd Bicycle toxin conjugates and uses thereof
JP2022532134A (ja) 2019-05-09 2022-07-13 バイスクルテクス・リミテッド Ｏｘ４０に特異的な二環式ペプチドリガンド
TW202110485A (zh) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
WO2021028686A1 (en) * 2019-08-13 2021-02-18 Bicycletx Limited Modified multimeric bicyclic peptide ligands
US11332500B2 (en) 2019-10-03 2022-05-17 Bicycletx Limited Heterotandem bicyclic peptide complexes
CN114760988A (zh) * 2019-11-27 2022-07-15 拜斯科技术开发有限公司 对EphA2具有特异性的双环肽配体和其用途
EP4165414A1 (en) 2020-06-12 2023-04-19 BicycleTX Limited Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
CA3189761A1 (en) * 2020-08-03 2022-02-10 Gemma Mudd Peptide-based linkers
CA3206529A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Heterotandem bicyclic peptide complexes
EP4274597A1 (en) 2021-01-11 2023-11-15 BicycleTX Limited Methods for treating cancer
CN117693519A (zh) 2021-05-25 2024-03-12 瓦克斯细胞生物 基于单体拟抗体的嵌合抗原受体和包含其的免疫细胞
WO2023020485A1 (zh) * 2021-08-17 2023-02-23 南京明德新药研发有限公司 具有新颖结构的多肽药物偶联物及其应用
CA3235116A1 (en) * 2021-10-14 2023-04-20 Xizang Haisco Pharmaceutical Co., Ltd. Epha2 bicyclic peptide ligand and conjugate thereof
KR20230140746A (ko) * 2022-03-30 2023-10-10 연세대학교 산학협력단 암전이의 검출용 신규 바이오마커

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
DE69938353T2 (de) 1998-09-24 2009-03-05 Indiana University Research and Technology Corp., Indianapolis Wasserlösliche lumineszente quantum-dots sowie deren biokonjugate
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
AP1905A (en) 1999-12-10 2008-10-20 Pfizer Prod Inc Pyrrolo[2,3-d] Pyrimidine Compounds.
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2477163C (en) 2002-02-21 2010-07-27 Institute Of Virology Soluble form of carbonic anhydrase ix (s-ca-ix), assays to detect s-ca ix, and ca ix's coexpression with her-2/neu/c-erbb-2, and ca ix-specific monoclonal antibodies to non-immunodominant epitopes
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
EP1852441B1 (en) * 2002-09-24 2012-03-28 The Burnham Institute Agents that modulate EPH receptor activity
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
BRPI0409063A (pt) 2003-04-03 2006-03-28 Semafore Pharmaceuticals Inc pró medicamentos de inibidor de pi-3 cinase
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
EP2511297B1 (en) 2004-02-06 2015-04-08 MorphoSys AG Anti-CD38 human antibodies and uses therefor
US7151047B2 (en) 2004-04-28 2006-12-19 Warren Chan Stable, water-soluble quantum dot, method of preparation and conjugates thereof
US7932260B2 (en) 2004-05-13 2011-04-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
PL1844337T3 (pl) 2005-01-24 2013-12-31 Pepscan Systems Bv Związki wiążące, związki immunogenne i peptydomimetyki
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
AU2006302179C1 (en) 2005-10-07 2013-06-20 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
RU2589878C2 (ru) 2005-11-01 2016-07-10 Таргеджен, Инк. Би-арил-мета-пиримидиновые ингибиторы киназ
LT2474545T (lt) 2005-12-13 2017-02-27 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
NZ572812A (en) 2006-04-26 2010-09-30 Hoffmann La Roche THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR
USRE47123E1 (en) * 2006-07-18 2018-11-13 Sanofi EPHA2 receptor antagonist antibodies
US7666392B2 (en) 2006-09-15 2010-02-23 Siemens Medical Solutions Usa, Inc. Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
EP2201840B1 (en) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
ES2557930T3 (es) 2007-03-12 2016-01-29 Ym Biosciences Australia Pty Ltd Compuestos de fenilaminopirimidina y usos de los mismos
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AU2008265928A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Synergistic treatment of cells that express EphA2 and ErbB2
EP2653545A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and compositions
RS55263B1 (sr) 2008-03-11 2017-02-28 Incyte Holdings Corp Derivati azetidina i ciklobutana kao jak inhibitori
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
JP6254527B2 (ja) 2011-10-07 2017-12-27 バイサイクル・セラピューティクス・リミテッド 構造化ポリペプチドの特異性のモジュレーション
ES2808726T3 (es) 2013-03-12 2021-03-01 Molecular Templates Inc Inmunotoxinas de unión a CD20 para inducir la internalización celular y procedimientos que usan las mismas
US20140274759A1 (en) * 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
WO2014190257A2 (en) 2013-05-23 2014-11-27 Ohio State Innovation Foundation Chemical synthesis and screening of bicyclic peptide libraries
CN105683211B (zh) 2013-10-28 2020-10-20 拜斯科阿迪有限公司 新型多肽
EP3140653B1 (en) 2014-05-08 2022-05-11 Novodiax, Inc. Direct immunohistochemistry assay
EP3149025B1 (en) 2014-05-21 2019-06-26 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
PL3215518T3 (pl) 2014-10-29 2021-08-23 Bicyclerd Limited Bicykliczne ligandy peptydowe swoiste wobec MT1-MMP
WO2016171242A1 (ja) 2015-04-24 2016-10-27 第一三共株式会社 Ｅｐｈａ２の検出
CA2982413A1 (en) * 2015-04-28 2016-11-03 Ecole Polytechnique Federale De Lausanne (Epfl) Novel inhibitors of the enzyme activated factor xii (fxiia)
US20190298681A1 (en) 2016-03-16 2019-10-03 Merrimack Pharmaceuticals, Inc. Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) and Related Diagnostics
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
BR112018071612A2 (pt) 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
WO2018096365A1 (en) 2016-11-27 2018-05-31 Bicyclerd Limited Methods for treating cancer
JP7387440B2 (ja) 2016-12-23 2023-11-28 バイスクルテクス・リミテッド Ｍｔ１－ｍｍｐに結合するためのペプチドリガンド
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
WO2018127699A1 (en) 2017-01-06 2018-07-12 Bicyclerd Limited Compounds for treating cancer
IL268836B2 (en) 2017-02-24 2024-04-01 Macrogenics Inc Bispecific molecules that bind CD137 and cancer antigens and their uses
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
WO2018197893A1 (en) 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
ES2926195T3 (es) 2017-08-04 2022-10-24 Bicycletx Ltd Ligandos peptídicos bicíclicos específicos de CD137
US20200283482A1 (en) 2017-08-14 2020-09-10 Bicyclerd Limited Bicyclic peptide ligand prr-a conjugates and uses thereof
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
US11572370B2 (en) 2018-01-08 2023-02-07 Biohaven Therapeutics Ltd. CD16A binding agents and uses thereof
US10875894B2 (en) 2018-02-23 2020-12-29 Bicycletx Limited Multimeric bicyclic peptide ligands
BR112020020349A2 (pt) 2018-04-04 2021-01-05 Bicycletx Limited Complexos de peptídeos bicíclicos em heterotandem
AU2019272575A1 (en) 2018-05-21 2020-12-10 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by NK cells
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US10919937B2 (en) 2018-10-23 2021-02-16 Bicycletx Limited Bicyclic peptide ligands and uses thereof
US20220024982A1 (en) 2018-12-13 2022-01-27 Bicycletx Limited Bicyclic peptide ligands specific for mt1-mmp
WO2020131697A2 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
SG11202110828UA (en) 2019-04-02 2021-10-28 Bicycletx Ltd Bicycle toxin conjugates and uses thereof
JP2022532134A (ja) 2019-05-09 2022-07-13 バイスクルテクス・リミテッド Ｏｘ４０に特異的な二環式ペプチドリガンド
TW202110485A (zh) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
WO2021028686A1 (en) 2019-08-13 2021-02-18 Bicycletx Limited Modified multimeric bicyclic peptide ligands
US11332500B2 (en) 2019-10-03 2022-05-17 Bicycletx Limited Heterotandem bicyclic peptide complexes
CN114760988A (zh) 2019-11-27 2022-07-15 拜斯科技术开发有限公司 对EphA2具有特异性的双环肽配体和其用途
EP4165414A1 (en) 2020-06-12 2023-04-19 BicycleTX Limited Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
US20240240255A1 (en) 2020-08-17 2024-07-18 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
CA3206529A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Heterotandem bicyclic peptide complexes
EP4274597A1 (en) 2021-01-11 2023-11-15 BicycleTX Limited Methods for treating cancer

Also Published As

Publication number Publication date
SG11202005494QA (en) 2020-07-29
BR112020012246A2 (pt) 2020-11-24
ES2922632T3 (es) 2022-09-19
TWI825046B (zh) 2023-12-11
AU2018387418B2 (en) 2024-01-25
JP2021506936A (ja) 2021-02-22
CA3086257A1 (en) 2019-06-27
LT3727460T (lt) 2022-07-25
KR20200105839A (ko) 2020-09-09
EP3727461A1 (en) 2020-10-28
HRP20220871T1 (hr) 2022-12-23
US20190184025A1 (en) 2019-06-20
CN111741771A (zh) 2020-10-02
AU2024202618A1 (en) 2024-06-13
AU2018387417B2 (en) 2023-11-23
WO2019122860A1 (en) 2019-06-27
AU2018387417A1 (en) 2020-07-30
DK3727460T3 (da) 2022-07-11
JP2021506910A (ja) 2021-02-22
JP7293231B2 (ja) 2023-06-19
BR112020012349A2 (pt) 2020-11-24
JP7503689B2 (ja) 2024-06-20
IL275440A (en) 2020-08-31
JP2023130345A (ja) 2023-09-20
TW201927306A (zh) 2019-07-16
CN111787955B (zh) 2024-06-04
US20220289792A1 (en) 2022-09-15
IL275440B2 (en) 2024-03-01
EP4053145B1 (en) 2024-06-12
US20240189436A1 (en) 2024-06-13
JP7404241B2 (ja) 2023-12-25
SG11202005495UA (en) 2020-07-29
AU2018387418A1 (en) 2020-07-30
KR20200105840A (ko) 2020-09-09
EP3727460B1 (en) 2022-04-13
SI3727460T1 (sl) 2022-11-30
MX2020006474A (es) 2020-12-11
CN111787955A (zh) 2020-10-16
IL275437A (en) 2020-08-31
PH12020550929A1 (en) 2021-05-17
EP4053145A1 (en) 2022-09-07
US11696956B2 (en) 2023-07-11
US20240000957A1 (en) 2024-01-04
US11833211B2 (en) 2023-12-05
US20230144799A1 (en) 2023-05-11
CA3085253A1 (en) 2019-06-27
PL3727460T3 (pl) 2022-08-22
WO2019122863A1 (en) 2019-06-27
SA520412268B1 (ar) 2023-11-12
PT3727460T (pt) 2022-07-14
HUE059126T2 (hu) 2022-10-28
EP3727460A1 (en) 2020-10-28
IL275440B1 (en) 2023-11-01
US11484602B2 (en) 2022-11-01

Similar Documents

Publication Publication Date Title
PH12020550929A1 (en) Bicyclic peptide ligands specific for epha2
PH12020552179A1 (en) Bicyclic peptide ligands specific for nectin-4
NZ731185A (en) Bicyclic peptide ligands specific for mt1-mmp
MX2020008791A (es) Ligandos de peptidos biciclicos multimericos.
MX2021006991A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
MX2021013669A (es) Ligandos peptidicos biciclicos especificos para ox40.
MX2022006511A (es) Polipeptidos efectores de la sub-unidad a de la toxina shiga, andamiajes de los efectores de la toxina shiga, y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
SG11201807936VA (en) Cell injury inducing therapeutic drug for use in cancer therapy
MX2022004572A (es) Conjugados farmacologicos de ligandos peptidicos biciclicos.
WO2016094873A3 (en) Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
MX2022010703A (es) Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores.
NZ730563A (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX2018014456A (es) Anticuerpos contra alfa-sinucleina y sus usos.
MX2019010392A (es) Moleculas de fusion de ectodominios receptores de tgf-b y sus usos.
MX2018005886A (es) Composiciones y metodos para la expresion de polipeptidos biologicamente activos a partir de un vector unico para tratamiento de condiciones cardiacas y otras patologias.
EP4273258A3 (en) Proteins binding her2, nkg2d and cd16
MX2019000135A (es) Anticuerpos anti-transicion mesenquimal-epitelial (met) y usos de los mismos.
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
MY196747A (en) Cell injury inducing therapeutic drug for use in cancer therapy
MX2021006989A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
MX2020012273A (es) Proteína de union a nkg2d, cd16 y proteína de activación de fibroblastos.
PH12019550275A1 (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
MX2019014448A (es) Inmunoglobulinas de enlace a mmp13.
MX2023005624A (es) Ligandos peptidicos biciclicos especificos para el receptor de transferrina 1 (tfr1).
PH12019501682A1 (en) Rorgamma modulators and uses thereof